A Phase 2 interventional study of AZD9833 in HER2-negative Breast Cancer, sponsored by AstraZeneca. Completed at 12 sites in 3 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.
Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 10th largest by enrollment, is one of 3 that started in 2020, is one of 3 in phase 2, and was the 3rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, France, Germany and 6 more countries
Ages 18–130
AstraZeneca · Sites in United States, United Kingdom
Ages 18+ · Women only
MedSIR · Sites in Germany, Spain
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 36 more countries
Ages 18–130
By country, each count listing its studies:
AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, AZD9833 is the treatment under test here. Read study by study →
17 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 150 across the 17 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 69th largest by enrollment of the 125 interventional ones that give a count, is one of 11 that started in 2020, is one of 31 in phase 2, and was the 133rd registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
1 of the studies testing AZD9833 in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing AZD9833 in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with primary breast cancer
The study will be conducted in approximately 20 study centers across 3 countries and will be conducted in three stages (stage 1, stage 2 and stage 3). After the screening visit and confirmation of eligibility, evaluable participants will be enrolled across treatment groups. In stage 1, up to 24 evaluable participants across two treatment groups will be enrolled. A Safety and Data Monitoring Committee will convene to review stage 1 data and decide whether further treatment groups are required in stage 2. Stage 2 will include participants across up to 3 treatment groups. Stage 3 will include two treatment groups:
Stage 1 Group 1: AZD9833 Dose A once daily Group 2: AZD9833 Dose B once daily
Stage 2 Group 1: AZD9833 Dose A once daily Group 2: AZD9833 Dose B once daily Group 3: AZD9833 Dose C once daily
Stage 3 Group 1: AZD9833 Dose A once daily Group 2: AZD9833 Dose B once daily
Adverse events and concomitant medications information will be collected throughout the study. Thereafter there will be 28-day follow-up visit after discontinuation of study treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
status defined as meeting at least one of the following criteria:
According to the local laboratory participants must have:
Exclusion Criteria:
Intervention with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.
Drug: AZD9833
Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.
Drug: AZD9833
Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 2 of the study.
Drug: AZD9833
Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 2 of the study.
Drug: AZD9833
Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.
Drug: AZD9833
Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 3 of the study.
Drug: AZD9833
Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 3 of the study.
Drug: AZD9833
AZD9833 tablets will be administered orally.
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)
The pharmacodynamic (PD) effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by immunohistochemistry (IHC) method. The percentage change was calculated from an analysis of covariance (ANCVOA) model adjusting for baseline ER score and day of on-treatment biopsy.
Time frame: Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Percentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)
The PD effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline ER H-score \< 10. The percentage change was calculated from ANCVOA model adjusting for baseline ER score and day of on-treatment biopsy.
Time frame: Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Percentage Change From Baseline in Progesterone Receptor (PgR) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis)
The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.
Time frame: Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Percentage Change From Baseline in PgR Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)
The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline PgR H-score \< 10. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.
Time frame: Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Primary Analysis)
The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.
Time frame: Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis)
The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline Ki67 labelling index \<5%. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.
Time frame: Baseline (Screening Day -21 to 1) to Biopsy Day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])
Number of Patients With Adverse Events (AEs)
The safety and tolerability of AZD9833 in this patient population was evaluated.
Time frame: From screening (Day -21 to 1) through 28-day follow-up (Upto 2 months)
Plasma Concentrations of AZD9833
The plasma concentration of AZD9833 in this participant population was evaluated
Time frame: Days 5-7 or Days 12-15 (Pre and Post biopsy)
The study was conducted at 13 sites in 3 countries between November 2, 2020 and June 19, 2023.
| Milestone | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Started | 30 | 33 | 13 | 30 | 29 |
| Completed | 29 | 33 | 12 | 29 | 27 |
| Not completed | 1 | 0 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 |
The pharmacodynamic (PD) effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by immunohistochemistry (IHC) method. The percentage change was calculated from an analysis of covariance (ANCVOA) model adjusting for baseline ER score and day of on-treatment biopsy.
| Percentage change from baseline | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) | -62.7 (-67.46 to -57.93) | -62.8 (-67.13 to -58.43) | -67.1 (-74.49 to -59.74) | -66.9 (-72.34 to -61.46) | -65.0 (-70.27 to -59.81) |
The PD effect of AZD9833 on ER expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline ER H-score \< 10. The percentage change was calculated from ANCVOA model adjusting for baseline ER score and day of on-treatment biopsy.
| Percentage change from baseline | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Percentage Change From Baseline in ER Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis) | -62.1 (-67.00 to -57.25) | -62.3 (-66.64 to -57.88) | -66.6 (-74.00 to -59.14) | -66.9 (-72.34 to -61.46) | -65.0 (-70.27 to -59.81) |
The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.
| Percentage change from baseline | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Progesterone Receptor (PgR) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) | 194.8 (25.50 to 364.03) | -3.0 (-158.37 to 152.36) | 170.3 (-89.67 to 430.33) | -24.2 (-547.03 to 498.69) | 463.8 (-38.45 to 966.02) |
The PD effects of AZD9833 on PgR expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline PgR H-score \< 10. The percentage change was calculated from an ANCOVA model adjusting for baseline PgR score and day of on-treatment biopsy.
| Percentage change from baseline | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Percentage Change From Baseline in PgR Expression Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis) | -35.2 (-45.86 to -24.57) | -44.0 (-53.09 to -34.90) | -36.7 (-52.96 to -20.52) | -61.8 (-76.93 to -46.62) | -55.0 (-71.29 to -38.78) |
The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.
| Percentage change from baseline | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Primary Analysis) | -40.3 (-52.78 to -24.49) | -79.4 (-83.37 to -74.55) | -78.2 (-84.82 to -68.77) | -73.0 (-79.42 to -64.64) | -77.5 (-82.68 to -70.86) |
The PD effect of AZD9833 on antigen Ki-67 expression comparing pre- and on-treatment tumour samples in women with early breast cancer after 5 to 7 days and 12 to 15 days of AZD9833 treatment was assessed. The assessment was done by IHC method. The sensitivity analysis excluded any patients who were HER2-positive patient by central assessment as well as patients with baseline Ki67 labelling index \<5%. The percentage change was calculated from an ANCOVA model adjusting for log baseline Ki67 index and day of on-treatment biopsy. The Ki-67 index data were log transformed prior to analysis, with results back-transformed to represent percentage change.
| Percentage change from baseline | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Ki-67 Labelling Index Between Pre- and On-treatment Tumour Samples (Sensitivity Analysis) | -49.3 (-62.18 to -31.96) | -81.3 (-85.14 to -76.49) | -78.9 (-85.37 to -69.46) | -81.7 (-86.45 to -75.24) | -81.9 (-86.38 to -75.88) |
The safety and tolerability of AZD9833 in this patient population was evaluated.
| Participants | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Any AE | 9 | 17 | 9 | 11 | 19 |
| Any AE possibly related to treatment | 4 | 14 | 6 | 10 | 17 |
| Any AE of CTCAE grade 3 or higher | 0 | 1 | 0 | 0 | 0 |
| Any AE of CTCAE grade 3 or higher, possibly related to treatment | 0 | 1 | 0 | 0 | 0 |
| Any AE with outcome = death | 0 | 0 | 0 | 0 | 0 |
| Any AE with outcome = death, possibly related to treatment | 0 | 0 | 0 | 0 | 0 |
| Any SAE (including events with outcome = death) | 0 | 0 | 0 | 0 | 0 |
| Any SAE (including events with outcome = death), possibly related to treatment | 0 | 0 | 0 | 0 | 0 |
| Any SAE leading to discontinuation of treatment | 0 | 0 | 0 | 0 | 0 |
| Any SAE leading to discontinuation of treatment, possibly related to treatment | 0 | 0 | 0 | 0 | 0 |
| Any AE leading to discontinuation of treatment | 0 | 0 | 1 | 0 | 2 |
| Any AE leading to discontinuation of treatment, possibly related to treatment | 0 | 0 | 0 | 0 | 2 |
| Any AE leading to dose modification of treatment | 0 | 0 | 0 | 0 | 0 |
| Any AE leading to dose modification of treatment, possibly related to treatment | 0 | 0 | 0 | 0 | 0 |
| Any other significant AEs | 0 | 0 | 0 | 0 | 0 |
The plasma concentration of AZD9833 in this participant population was evaluated
| Nanograms per milliliter | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Days 5-7 or Days 12-15 (Pre-biopsy) | 50.712 ± 74.1 | 122.134 ± 103.8 | 180.773 ± 173.3 | 46.939 ± 56.3 | 120.516 ± 70.0 |
| Days 5-7 or Days 12-15 (Post-biopsy) | 58.304 ± 62.2 | 142.916 ± 102.4 | 213.446 ± 175.6 | 54.075 ± 42.8 | 137.687 ± 55.4 |
Collected over From screening (Day -21 to 1) through 28-day follow-up (Up to 2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD9833 75 mg (Stage 1 + 2) | 0/30 (0%) | 0/30 (0%) | 7/30 (23.3%) |
| AZD9833 150 mg (Stage 1 + 2) | 0/33 (0%) | 0/33 (0%) | 17/33 (51.5%) |
| AZD9833 300 mg (Stage 2) | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| AZD9833 75 mg (Stage 3) | 0/30 (0%) | 0/30 (0%) | 11/30 (36.7%) |
| AZD9833 150 mg (Stage 3) | 0/29 (0%) | 0/29 (0%) | 19/29 (65.5%) |
| Event | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) |
|---|---|---|---|---|---|
| Visual impairmentEye disorders | 0/30 | 5/33 | 3/13 | 6/30 | 7/29 |
| HypertensionVascular disorders | 1/30 | 2/33 | 3/13 | 1/30 | 4/29 |
| DiplopiaEye disorders | 0/30 | 4/33 | 1/13 | 0/30 | 5/29 |
| PhotopsiaEye disorders | 2/30 | 4/33 | 2/13 | 3/30 | 4/29 |
| NauseaGastrointestinal disorders | 4/30 | 3/33 | 1/13 | 2/30 | 1/29 |
| HeadacheNervous system disorders | 2/30 | 3/33 | 1/13 | 3/30 | 3/29 |
| DizzinessNervous system disorders | 0/30 | 2/33 | 1/13 | 2/30 | 3/29 |
| Sinus bradycardiaCardiac disorders | 0/30 | 0/33 | 0/13 | 0/30 | 3/29 |
| FatigueGeneral disorders | 2/30 | 3/33 | 0/13 | 0/30 | 0/29 |
| COVID-19Infections and infestations | 0/30 | 0/33 | 1/13 | 0/30 | 0/29 |
Safety Analysis Set was defined as all patients who received any amount of study treatment, regardless of whether that was the randomized therapy intended.
| Age, Continuous(Years) | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) | Total |
|---|---|---|---|---|---|---|
| Mean | 62.0 ± 7.35 | 65.7 ± 7.53 | 66.3 ± 8.20 | 64.0 ± 8.65 | 67.2 ± 10.03 | 64.9 ± 8.49 |
| Sex: Female, Male(Participants) | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) | Total |
|---|---|---|---|---|---|---|
| Female | 30 | 33 | 13 | 30 | 29 | 135 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 30 | 33 | 13 | 30 | 29 | 135 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | AZD9833 75 mg (Stage 1 + 2) | AZD9833 150 mg (Stage 1 + 2) | AZD9833 300 mg (Stage 2) | AZD9833 75 mg (Stage 3) | AZD9833 150 mg (Stage 3) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 4 | 5 | 9 |
| Not Hispanic or Latino | 29 | 32 | 13 | 26 | 24 | 124 |
| Other | 1 | 1 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2020 to primary completion in Jun 2023, 31 months.
Results were first posted in Jan 2025, 1 year 7 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 31 months is close to that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD9833